PTC Therapeutics | PTCT - Sales Revenues


PTC Therapeutics reported $273M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Cytokinetics USD 19.35M 1.59M Mar/2026
Daiichi Sankyo JPY 587B 28.89B Mar/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 7B 930M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
TG Therapeutics USD 194.8M 2.23M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026